Nominee's Key Links:
Bio: https://twitter.com/hervk102/status/1851645015354716524
Resume or CV: https://twitter.com/hervk102/status/1851645015354716524
Writing or Publications: Laderoute MP. A new paradigm about HERV-K102 particle production and blocked release to explain cortisol mediated immunosenescence and age-associated risk of chronic disease. Discov Med. 2015 Dec;20:379-91. Laderoute, M. Antibody Dependent Enhancement (ADE) of Infection into Macrophages Validates the Importance of HERV-K102 Particle Production for Pandemic Preparedness. Preprints 2023, 2023120185. https://www.preprints.org/manuscript/202312.0185/v2. DOI: 10.20944/preprints202312.0185.v2,
Website: hervk102.substack.com
Video: https://rumble.com/v51idm2-dr.-marian-laderoute-jun-01-2024-regina-saskatchewan.html
Socials: hervk102.twitter.com
Agency or agencies for which nominator feels nominee is best suited:
Department of Health and Human Services
Organization name(s) and position(s) for which nominator feels nominee is best suited: <strong
Consultant to HHS/WH on how to reduce chronic disease in adults and for pandemic preparedness. .
Policies which the nominator knows the nominee supports or in which they have expertise:
1) Reversing & preventing chronic disease (about 25 years clinical experience using nutraceuticals, ISM Ottawa, Ontario Canada) by blocking immunosenescence of macrophages.
2) Minimizing risks of iatrogenic (medical intervention) infections (1996 - 2011 Health Canada, LCDC, Public Health Agency of Canada)
3) Blood tests useful for determining health of populations and for performance measurement of success of new policies
4) Pandemic preparedness (was the Research Manager for the Blood Zoonotics Unit at the Public Health Agency of Canada, discovered the HERV-K102 virus anti-virus protection system critical for prevention/recovery of COVID-19)
Nominator's thoughts on what would make this nominee a valuable member of a future Trump Unity Government
If you go to the twitter reference https://twitter.com/hervk102/status/1851645015354716524 where the brief C.V. is posted, I think you will see how Dr. Laderoute meets the various qualifications.
She has also sworn testimony describing her expertise and accomplishments [https://rumble.com/v51idm2-dr.-marian-laderoute-jun-01-2024-regina-saskatchewan.html], which some have viewed as impressive.
Dr. Laderoute has never taken a penny from Big Pharma, and has never received funding outside of the Chief Scientists Office at Health Canada, and the Blood Safety Program Research Budget. Dr. Laderoute has never been in a conflict of interest. Even the patent applications and patents, inventors have no rights. Indeed, PHAC more recently abandoned their patents, meaning anyone can use the HERV-K102 virus-anti-virus discovery without restrictions. The latter was the intended goal of Dr. Laderoute, to prevent Big Pharma from access to these patents where it was thought they would keep this discovery unavailable to the public.
Dr. Laderoute is a world expert on preventing and reversing chronic diseases by blocking the immunosenescence of macrophages and has over 25 years of RELEVANT clinical/lab experience (mostly cancer patients). Simply the key is to use alpha-fetoprotein (AFP) antagonists (such as ivermectin, vitamin D3, zinc, DHEA analogues such as 7-keto-DHEA, genistein etc) which target the cause and to avoid drugs, herbal medicines and other supplements that may inhibit the activation of macrophages due to their anti-inflammatory actions. Dr. Laderoute is well versed in what enhances macrophage activation and what inhibits.
MPL new immunosens paradigm 2015|690x388
At the present time, there is an ever growing epidemic of rapidly progressing tumors secondary to IgG4 antibodies to spike protein which knocks out critical “trained (INNATE) immunity” every time there is an exposure to the spike protein (spike vaccine, shedding, and SARS-CoV-2 infection). This damage is due to spike binding to the antibody which after a conformational change allows its binding to FCGR2B which blocks macrophage activation. The available evidence such as from Dr. William Makis indicates that ivermectin protocols are rescuing these adults from certain death. In children who have had two doses of the mRNA vaccines we are seeing an increased risk of infections generally including *Mycoplasma pneumoniae’. It is thought these risks would also respond to AFP antagonists. Dr. Laderoute started her career working on how to make malignant tumors benign. She was first in 1994 to accurately project that the malignant nature of tumors is a phenotype caused by the excess activity of AFP. It has been said that Dr. Laderoute is decades ahead of the rest.
See x.com for more information revealing that Dr. Marian Laderoute’s expertise is not only with respect to the cause of chronic disease (in adults) but she is also a NOTABLE expert in pandemic preparedness due to her proof that it is the shedding of the HERV-K102 protector particles by way of sebum which creates HERD Immunity! This herd immunity is lost when spike mRNA gene therapy products are inappropriately used for immunization.
Dr. Laderoute is Canadian and retired. However, she would be a welcomed addition to any Task Force, Advisory Committee and/or medical scientist consultant to Robert F Kennedy, Jr. on reducing chronic disease in adults and pandemic planning. She had also been credited as an auditor for performance measurement at the Public Health Agency of Canada (PHAC) and could help direct the implementation of measures to evaluate new policies intended to improve health. Since she is assertive, polite, knowledgeable and caring, she is a great team player and well experienced at committee meetings.
In an “X” (twitter) post [ x.com ], Dr. Laderoute suggested that an increased risk of “turbo cancers” exists for people with spike IgG4 antibodies whereas those that keep spike IgG1/3 may be at increased risk of shedding and/or long COVID-19/post-C19 Vax syndrome. In either case, to understand the pathology, and thus to generate the ability to influence outcomes, one must test for HERV-K102 activation. This testing involves HERV-K102 cDNA particle levels in DNA isolated from plasma, gene copy levels found in genomic DNA isolated from plasma, HERV-K102 envelope antibodies in serum and levels of gamma-delta 2 T cells in PBMCs that recognize HERV-K102 envelope (method to be developed) as was described in Laderoute MP et al, 2007, AIDS. AS part of the MAHA objectives, the spike mRNA gene therapy shots caused a lot of chronic illness that must also be dealt with. We need a strong voice at MAHA to push for the HERV-K102 activation methods to be incorporated to study objective improvements to these polar opposite diseases (too much HERV-K102 activation not generating recovery (long COVID-19) and not enough HERV-K102 activation (turbo cancers) to mediate recovery. Fortunately both types of diseases appear to be responsive to ivermectin therapy.
We need Dr. Marian Laderoute, as a medical scientist consultant to MAHA to help guide what is prioritized as testing methods for
Blockquote
performance measurement
Blockquote of the expected sweeping changes to how health care is managed under the MAHA objectives.
